Skip to main content
Top
Published in: Neurological Sciences 2/2011

01-04-2011 | Brief Communication

Serum uric acid levels in multiple sclerosis patients inversely correlate with disability

Authors: A. L. Guerrero, F. Gutiérrez, F. Iglesias, J. Martín-Polo, S. Merino, J. I. Martín-Serradilla, E. Laherrán, M. A. Tejero

Published in: Neurological Sciences | Issue 2/2011

Login to get access

Abstract

Uric acid (UA) is an endogenous antioxidant. Some studies have described that multiple sclerosis (MS) patients have lower serum UA levels than controls, although it has not been established whether UA is primarily deficient, or secondarily reduced due to its scavenging activity. UA has also been proposed as an indicator of disease activity. We, retrospectively, reviewed 478 serum UA levels obtained in 94 MS patients. Ninety samples were collected during a relapse. Correlation between UA levels obtained during a relapse or in a relapse-free period, and comparison between UA and expanded disability status scale (EDSS) score was tested using a two-tailed Student’s t test and Spearman correlation coefficients test. UA levels were significantly lower when measured during a relapse (n 90) than in a remission period (n 368) (r −0.16, p 0.003) UA levels measured outside a relapse inversely correlated with EDSS score (r −0.15, p 0.001). Lower uric acid levels in MS patients are associated with clinical relapse. This is the first description of an inverse correlation of serum UA levels with disability as assessed by EDSS score.
Literature
1.
go back to reference Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci USA 99(25):16303–16308PubMedCrossRef Scott GS, Spitsin SV, Kean RB, Mikheeva T, Koprowski H, Hooper DC (2002) Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci USA 99(25):16303–16308PubMedCrossRef
2.
go back to reference Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B (2001) In vivo damage of CNS myelin and axons induced by peroxynitrite. Neuroreport 12(16):3637–3644 Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B (2001) In vivo damage of CNS myelin and axons induced by peroxynitrite. Neuroreport 12(16):3637–3644
3.
go back to reference Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I et al (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95(2):675–680PubMedCrossRef Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I et al (1998) Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95(2):675–680PubMedCrossRef
4.
go back to reference Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patiens correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9:221–226PubMedCrossRef Toncev G, Milicic B, Toncev S, Samardzic G (2002) Serum uric acid levels in multiple sclerosis patiens correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9:221–226PubMedCrossRef
5.
go back to reference Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S, Miljkovic D et al (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248(2):121–126PubMedCrossRef Drulovic J, Dujmovic I, Stojsavljevic N, Mesaros S, Andjelkovic S, Miljkovic D et al (2001) Uric acid levels in sera from patients with multiple sclerosis. J Neurol 248(2):121–126PubMedCrossRef
6.
go back to reference Scott GS, Hooper DC (2001) The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 56(1):95–100PubMedCrossRef Scott GS, Hooper DC (2001) The role of uric acid in protection against peroxynitrite-mediated pathology. Med Hypotheses 56(1):95–100PubMedCrossRef
7.
go back to reference Mostert JP, Ramsaransing GSM, Heersema DJ, Heerings M, Wilczak N, De Keyser J (2005) Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. J Neurol Sci 231:41–44PubMedCrossRef Mostert JP, Ramsaransing GSM, Heersema DJ, Heerings M, Wilczak N, De Keyser J (2005) Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses. J Neurol Sci 231:41–44PubMedCrossRef
8.
go back to reference Karg E, Klivenyi P, Nemeth I, Bencsik K, Pinter S, Vecsei L (1999) Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 246:533–539PubMedCrossRef Karg E, Klivenyi P, Nemeth I, Bencsik K, Pinter S, Vecsei L (1999) Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 246:533–539PubMedCrossRef
9.
go back to reference Ramsaransing GSM, Heersema DJ, De Keyser J (2005) Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs progressive multiple sclerosis. Eur J Neurol 12:514–518PubMedCrossRef Ramsaransing GSM, Heersema DJ, De Keyser J (2005) Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs progressive multiple sclerosis. Eur J Neurol 12:514–518PubMedCrossRef
10.
go back to reference Peng F, Zhong X, Deng X, Qiu W, Wu A, Long Y et al (2010) Serum uric acid levels and neuromyelitis optica. J Neurol 257:1021–1026PubMedCrossRef Peng F, Zhong X, Deng X, Qiu W, Wu A, Long Y et al (2010) Serum uric acid levels and neuromyelitis optica. J Neurol 257:1021–1026PubMedCrossRef
11.
go back to reference Salemi G, Gueli MC, Vitale F, Battaglieri F, Guglielmini E, Ragonese P et al (2010) Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 9:19–21PubMedCrossRef Salemi G, Gueli MC, Vitale F, Battaglieri F, Guglielmini E, Ragonese P et al (2010) Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients. Lipids Health Dis 9:19–21PubMedCrossRef
12.
go back to reference Massa J, O’Reilly E, Munger KL, Delorenze GN, Ascherio A (2009) Serum uric acid and risk of multiple sclerosis. J Neurol 256:1643–1648PubMedCrossRef Massa J, O’Reilly E, Munger KL, Delorenze GN, Ascherio A (2009) Serum uric acid and risk of multiple sclerosis. J Neurol 256:1643–1648PubMedCrossRef
13.
go back to reference Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A et al (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42:1001–1006PubMedCrossRef Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A et al (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42:1001–1006PubMedCrossRef
14.
go back to reference Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, ARRU G et al (2002) Serum uric acid and multiple sclerosis. Neurol Sci 23(4):183–188PubMedCrossRef Sotgiu S, Pugliatti M, Sanna A, Sotgiu A, Fois ML, ARRU G et al (2002) Serum uric acid and multiple sclerosis. Neurol Sci 23(4):183–188PubMedCrossRef
15.
go back to reference Peng F, Zhang B, Zhong X, Li J, Xu G, Hu X et al (2008) Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 14:188–196PubMedCrossRef Peng F, Zhang B, Zhong X, Li J, Xu G, Hu X et al (2008) Serum uric acid levels of patients with multiple sclerosis and other neurological diseases. Mult Scler 14:188–196PubMedCrossRef
16.
go back to reference Toncev G, Milicic B, Toncev S, Samardzic G (2002) High-dose methylprednisolone theraphy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 40:505–508PubMedCrossRef Toncev G, Milicic B, Toncev S, Samardzic G (2002) High-dose methylprednisolone theraphy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 40:505–508PubMedCrossRef
17.
go back to reference Guerrero AL, Martín-Polo J, Laherrán E, Gutiérrez F, Iglesias F, Tejero MA et al (2008) Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 15:394–397PubMedCrossRef Guerrero AL, Martín-Polo J, Laherrán E, Gutiérrez F, Iglesias F, Tejero MA et al (2008) Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment. Eur J Neurol 15:394–397PubMedCrossRef
18.
go back to reference Constantinescu CS, Freitag P, Kappos L (2000) Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with Glatiramer acetate for multiple sclerosis. Mult Scler 6:378–381PubMed Constantinescu CS, Freitag P, Kappos L (2000) Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with Glatiramer acetate for multiple sclerosis. Mult Scler 6:378–381PubMed
19.
go back to reference Kanabrocki EL, Ryan MD, Hermida RC, Ayala DE, McCormick JB, Dawson S et al (2008) Uric acid and renal function in Multiple Sclerosis. Clin Ter 159:35–40 Kanabrocki EL, Ryan MD, Hermida RC, Ayala DE, McCormick JB, Dawson S et al (2008) Uric acid and renal function in Multiple Sclerosis. Clin Ter 159:35–40
20.
go back to reference Gonsette RE, Sindic C, D′hooghe MB, De Deyn PP, Medaer R, Michotte A et al (2010) Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon beta in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler 16:455–462PubMedCrossRef Gonsette RE, Sindic C, D′hooghe MB, De Deyn PP, Medaer R, Michotte A et al (2010) Boosting endogenous neuroprotection in multiple sclerosis: the association of inosine and interferon beta in relapsing-remitting multiple sclerosis (ASIIMS) trial. Mult Scler 16:455–462PubMedCrossRef
Metadata
Title
Serum uric acid levels in multiple sclerosis patients inversely correlate with disability
Authors
A. L. Guerrero
F. Gutiérrez
F. Iglesias
J. Martín-Polo
S. Merino
J. I. Martín-Serradilla
E. Laherrán
M. A. Tejero
Publication date
01-04-2011
Publisher
Springer Milan
Published in
Neurological Sciences / Issue 2/2011
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-011-0488-5

Other articles of this Issue 2/2011

Neurological Sciences 2/2011 Go to the issue